SOURCE: CymaBay Therapeutics

CymaBay Therapeutics Logo

January 24, 2014 09:00 ET

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link

NEWARK, CA--(Marketwired - January 24, 2014) - CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

For additional information about CymaBay visit www.cymabay.com.

Contact Information

  • Contact:
    Sujal Shah                                                
    CymaBay Therapeutics, Inc.                   
    (510) 293-8800                                       
    investors@cymabay.com                        

    Adam Cutler
    The Trout Group, LLC
    (646) 378-2936
    CymaBay@troutgroup.com